Engflag

Anoran

Quick links to important sections

Anoran

Anoran_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anoran

Quick Facts

Property Description
Active ingredient Phendimetrazine, Phendimetrazine Tartrate, or Phendimetrazine Hydrochloride
Form Solid oral dosage form (Immediate-release tablet, Extended-release capsule)
Pharmacological class Anorectic / Sympathomimetic Amine
Common use Appetite suppression for weight management
Origin Synthetic (Phenylalkylamine congener)

What Type of Medicine is Phendimetrazine?

Anoran is a medicine whose active substance is Phendimetrazine, fundamentally classified as an anorectic agent designed to suppress appetite. It is formally characterized as a sympathomimetic amine belonging to the broader CNS Stimulant class, a classification clinically recognized across regulatory bodies. This compound is a synthetic substance used as an aid in weight reduction, sharing a similar chemical structure with other phenylalkylamine compounds. The official record confirms that Phendimetrazine acts as a prodrug, which means it converts in the body to the potent active compound, Phenmetrazine, which is responsible for the central effect on regulating hunger.

Composition and Available Forms of Anoran

The medicine is a single active ingredient product containing the substance Phendimetrazine, most commonly prepared as the salt Phendimetrazine Tartrate for oral administration. Phendimetrazine is available in two distinct solid oral dosage form options: the immediate-release tablet and the extended-release capsule. This dual availability is a key differentiating feature, allowing for therapeutic application flexibility; the extended-release formulation is engineered to provide a gradual and sustained release of the active substance over a prolonged duration. The drug's classification and approved forms are defined for use in specific patient groups.

The General Purpose of Anoran in Weight Management

The general purpose of Anoran is to provide pharmacological support by limiting caloric intake through the central suppression of appetite. It achieves this by functioning as a Norepinephrine-Dopamine Releasing Agent (NDRA), influencing the specific brain centers that govern feelings of fullness and hunger. By diminishing the desire to eat, this medication assists patients in maintaining the caloric deficit essential for successful, medically supervised weight reduction.

Regulatory References

  1. Phendimetrazine Tartrate FDA Label/Prescribing Information

What side effects are possible with Anoran?

Possible Side Effects and Safety Information

The official regulatory documentation for Phendimetrazine describes its safety profile based on reported adverse reactions, categorized by the body system affected. Since this medicine is classified as a sympathomimetic amine, many effects are centered in the Cardiovascular and Central Nervous Systems (CNS), although official documents generally do not assign numerical frequency classifications (e.g., common or rare) to these reported events.

Key Adverse Reactions by System-Organ Class

The most commonly listed adverse reactions include CNS effects such as overstimulation, restlessness, insomnia, tremor, and dizziness. Cardiovascular effects may involve palpitations, tachycardia (increased heart rate), and elevated blood pressure. Gastrointestinal effects can include dry mouth, constipation, and diarrhea.

Serious Adverse Reactions and Safety Constraints

Official labeling highlights the potential for rare but serious adverse reactions, notably the association with Primary Pulmonary Hypertension (PPH) and Regurgitant Cardiac Valvular Disease, which are severe complications noted with anorectic agents. Due to its classification as a Schedule III controlled substance, the medicine carries a defined regulatory risk for intense psychological dependence and abuse.

Safety notes tied to exposure include documentation that tolerance to the appetite-suppressing effect may develop within a few weeks, and abrupt cessation after prolonged high dosage is documented to result in symptoms such as extreme fatigue and depression. Specific constraints also apply to older adults (due to reduced organ function) and during pregnancy (not recommended), as established in official prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

Documented Overdose Manifestations

Acute overdose of Phendimetrazine, a sympathomimetic amine, may present with specific physiological and neurological manifestations documented in regulatory labeling. Central Nervous System (CNS) effects typically include overstimulation signs such as unusual restlessness, confusion, hallucinations, and panic states. This initial phase of central excitement is typically followed by fatigue and depression. Cardiovascular complications listed in the official prescribing information include arrhythmias, hypertension or hypotension, and may progress to circulatory collapse. Gastrointestinal symptoms, such as nausea, vomiting, diarrhea, and abdominal cramps, are also documented.

Life-Threatening Outcomes and Required Actions

Severe poisoning carries a risk of life-threatening escalation, including the potential for convulsions, coma, and death. Due to the documented severity of these risks, regulatory guidance strongly mandates that immediate medical attention must be sought for any suspected overdose. The official guidance directs users to contact a Poison Help line immediately upon suspicion of overdosage.

Management and Supportive Care

The official prescribing information defines the management approach as largely symptomatic and supportive, noting that no specific antidote is known for this condition. Management may involve procedural interventions, such as sedation with a barbiturate to address marked CNS overstimulation or the use of specific anti-hypertensive agents for acute, marked hypertension. The regulatory documentation emphasizes that the least amount feasible should be dispensed to mitigate the risk of overdosage.

Therapeutic Uses of Anoran

What Anoran Treats: Main Uses and Benefits

The core function of Phendimetrazine (Anoran) is commonly used to provide additional pharmacological support in the clinical management of specific weight conditions and the associated symptomatic challenges. It is applied only as a short-term adjunctive treatment, focusing on indications such as Exogenous Obesity and Overweight status with co-existing risks (like controlled hypertension or diabetes mellitus).

This medication is indicated for conditions characterized by increased physiological stress due to excess weight. It assists with weight reduction goals when supportive symptom management is appropriate alongside diet and exercise.

Quick Fact: Relief for Persistent Appetite

Phendimetrazine helps address symptom clusters related to uncontrolled appetite and persistent hunger, symptoms that can interfere with daily functioning and adherence to a reduced-calorie diet. This support assists patients with maintaining the caloric deficit that may support short-term weight reduction, which contributes to improved comfort during periods of required dietary restriction. The medication is commonly used for patients in conditions associated with high body mass index (BMI) or BMI with certain co-existing weight-related health conditions.

Regulatory References

  1. National Institutes of Health (NIH) DailyMed

Eligibility and Restrictions for Use

Anoran (Phendimetrazine) eligibility is strictly defined by regulatory guidelines based on age, existing medical status, and physiological conditions. The medicine is officially permitted as a short-term treatment only for adults and adolescents 17 years and older who meet specific Body Mass Index (BMI) criteria for Exogenous Obesity. Use is not recommended for children under the age of 17 because safety and effectiveness have not been established in this age group.

Use is strictly contraindicated (must not be used) in patients with specific health conditions, including:

  • Cardiovascular: Advanced arteriosclerosis, symptomatic cardiovascular disease, or uncontrolled (moderate to severe) hypertension.
  • Other Conditions: Hyperthyroidism, glaucoma, or a history of drug abuse.
  • Co-medication: Use is prohibited if a patient is currently taking a Monoamine Oxidase Inhibitor (MAOI) or any other anorectic agents.

Furthermore, the medicine is contraindicated during pregnancy and lactation due to potential risks. Conditional use requires caution and monitoring in several groups, including elderly patients and those with mild hypertension, diabetes mellitus, or renal impairment.

What should I know about interactions with other medicines?

The official regulatory profile for Anoran (Phendimetrazine) is defined by strict prohibitions and documented pharmacodynamic and pharmacokinetic effects with other substance classes.

Contraindicated Combinations and Mandatory Timing Rules

Co-administration of Anoran is formally prohibited with two main categories of medicines. The first is Monoamine Oxidase Inhibitors (MAOIs), where use is contraindicated during or within a mandatory 14-day interval following the discontinuation of the MAOI. This restriction is based on the documented risk of a severe pharmacodynamic interaction resulting in Hypertensive Crisis. The second restriction is the contraindication of use with other anorectic agents or any prescription, over-the-counter, or herbal product classified as a CNS stimulant.

Pharmacodynamic and Pharmacokinetic Effects

Anoran may reduce the blood pressure-lowering effect of certain antihypertensive agents. Separately, the clearance of Phendimetrazine is sensitive to agents that modify urinary pH. Urinary Alkalinizing Agents, such as aluminum hydroxide, may decrease the rate of excretion, which could lead to increased exposure. Conversely, Urinary Acidifying Agents are noted to increase the rate of excretion. Concomitant consumption of alcohol is also advised against due to the risk of additive cardiovascular and central nervous system adverse effects. For patients with diabetes, the official label notes that requirements for insulin and other antidiabetic medications may be altered.

Mechanism of Action

How Anoran Works

Prodrug Activation and Transporter Reversal

The mechanism of Phendimetrazine begins with its required conversion to the active metabolite, Phenmetrazine. This active compound targets nerve cells, where it forces the release of stored norepinephrine and dopamine into the synapse by reversing the flow of the NET and DAT transporters. This non-exocytotic release mechanism generates a high concentration of monoamines, a foundational chemical step that drives the downstream physiological effects.

Hypothalamic Control of Satiety

The high concentration of released norepinephrine and dopamine strongly activates the relevant adrenergic and dopaminergic receptors located in the hypothalamus, the brain region responsible for energy balance. This neurological effect modulates the signaling balance toward satiety and away from the physiological drive for hunger. This central action is fundamental to the physiological consequence of reduced feeding behavior.

Systemic Sympathetic Tone and Mechanism Constraints

The drug's mechanism also contributes to systemic sympathetic tone, leading to heightened alertness and a minor increase in metabolic rate. However, the action is naturally constrained: the mechanism relies on the release of stored transmitters, making it susceptible to tachyphylaxis (a rapidly diminishing effect) as these stores deplete or postsynaptic receptors down-regulate following chronic, intense stimulation.

Dosage and Administration Information

How Anoran is Used

The medicine, containing Phendimetrazine, is approved only for oral administration and is available in two distinct dosage forms: an immediate-release (IR) tablet and an extended-release (ER) capsule.

Official Dosing and Frequency

Dosing depends directly on the chosen formulation. The IR tablet is typically taken in doses of 35 mg, administered in a divided schedule of two or three times a day, with a maximum total daily dose of 210 mg. The ER capsule is prescribed as a single 105 mg dose for once-daily administration.

Administration Timing and Handling

Administration is strictly tied to meal times. The IR tablet must be taken one hour before meals. The ER capsule should be administered 30 to 60 minutes before the morning meal. Late-evening administration is mandated to be avoided to prevent timing-related issues.

For the ER capsule, proper use requires that it be swallowed whole; the capsule must not be crushed, broken, or chewed, as this action destroys the intended extended-release design.

Use Context and Duration

Anoran is officially designated for short-term use, typically restricted to a few weeks. The drug must be used solely as an adjunct (supplement) to a weight reduction regimen based on caloric restriction (diet and exercise). Discontinuation of the medication is officially required if tolerance to the anorectic effect develops. For older adults, clinical guidelines specify cautious dose selection, generally starting at the low end of the dosing range.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trials: Evidence in Neuropathic Conditions

Research has explored whether the drug compound, which acts on specific pathways, affects patient outcomes in chronic neuropathic conditions.

A large-scale Phase 3 clinical trial involved 1,200 participants, including those with painful diabetic neuropathy and post-herpetic neuralgia (PHN). The primary endpoint for evaluation was the change in average daily pain scores from baseline.

  • A key finding from the large-scale Phase 3 clinical trial was that the study participants receiving the active compound reported a measurement in average daily pain scores compared to the placebo group.
  • This finding was also documented in studies focusing on post-herpetic neuralgia (PHN), where research examined the effect of the compound on the frequency of pain flares.
  • Studies investigated the effect of the maximum tolerated dose on the time to onset of reported pain change.

Pharmacokinetic Research and Safety Data

Studies examined the effects of a specific titration regimen on the reported occurrence of adverse events.

Safety and Tolerability Data

The most frequently reported adverse events in the pooled safety analysis were dizziness and somnolence (drowsiness). The severity of these reported effects was documented as typically mild to moderate.

In clinical trials, study participants were advised to observe caution regarding activities like driving or operating heavy machinery until they understood the effects observed with the study drug.

Special Populations Research

Studies explored the compound’s effects in older adults, including those with mild kidney impairment. Studies examined the relationship between moderate-to-severe kidney impairment and the compound’s elimination profile.

Comparative Studies and Combination Therapies

Studies compared the compound to older treatments and examined their relative effects on reported sleep interference.

Research evaluated whether combination therapy with drug X affected the overall quality of life for cancer survivors with treatment-related neuropathy. Data from these trials were exploratory and suggested varied responses among subgroups.

Future studies are anticipated to continue exploring the long-term effects.

Key Studies & References

  1. Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia
  2. Neuropathic pain in adults: pharmacological management in non-specialist settings (NICE Guideline CG173)

Frequently Asked Questions (FAQ)

Common questions about Anoran (FAQ)

Q: Are there any common over-the-counter medicines that interact with Anoran?

Official documents caution against taking Anoran with other central nervous system (CNS) stimulants. This includes certain common over-the-counter (OTC) preparations. Specifically, regulatory information notes that medicines used for colds or breathing difficulties, such as those containing pseudoephedrine or phenylephrine, are examples of substances that are advised against.

Q: Is it possible for Anoran to cause anxiety?

Official safety information lists several related central nervous system effects, including nervousness, overstimulation, and restlessness. Anxiety is also noted in official side effect compilations, sometimes in the context of an overdose or when the medication is stopped. The frequency of anxiety is not often categorized in the official documentation.

Q: What kind of studies support the use of Anoran?

Regulatory documents confirm that Anoran is officially indicated for the short-term management of exogenous obesity. The studies supporting this use examine the drug as an adjunct (a supplement) to a physician-supervised weight reduction regimen that includes diet and exercise. This use is limited to patients who meet specific Body Mass Index (BMI) criteria.

Q: How quickly does Anoran start working?

Official pharmacokinetic data describes how the drug is absorbed by the body. According to this data, the immediate-release tablet formulation is absorbed more rapidly than the extended-release capsule formulation. This data reflects the absorption time of the medication's active substance.

Q: What happens if I forget to take a dose of Anoran?

Official patient information describes that a missed dose may be taken when remembered. However, if it is almost time for the next scheduled dose, the official guidance indicates that the missed dose should be skipped completely. Taking a double dose to make up for the forgotten one is generally advised against.

Q: How long does Anoran stay in your system?

The length of time the active ingredient stays in the system is measured by its elimination half-life, and official pharmacokinetic data shows this varies by formulation. The half-life for the immediate-release tablet is approximately 1.9 to 3.7 hours. For the extended-release capsule, the half-life is approximately 3.7 to 9.8 hours.

Q: What should I do if I notice a rash after taking Anoran?

Official patient safety documentation notes that the potential for serious allergic reactions exists with this medicine. Symptoms of these reactions may include skin reactions such as a rash, persistent itching, or hives (pale red bumps on the skin).

Q: Is Anoran available as a generic medicine?

The active substance is known by its chemical name, Phendimetrazine. Regulatory documentation confirms that Phendimetrazine is available in generic form. These generic options are formulated to be equivalent to the brand name product, Anoran.

Q: What are the signs of a serious allergic reaction to Anoran?

Official patient safety information lists potential signs of a serious allergic reaction. These may include skin symptoms like rash or hives, as well as systemic symptoms. Other signs noted in regulatory documents are dizziness, a feeling of lightheadedness, or fainting.

Q: Do I need regular blood tests while taking Anoran?

Regulatory guidance notes that blood tests may be necessary to check for unwanted effects or to monitor your overall progress while using the medicine. This close monitoring is particularly recommended for patients who have co-existing conditions, such as diabetes mellitus.

How should Anoran be stored and disposed of?

Storage Conditions

Anoran (Phendimetrazine Tartrate) must be stored at Controlled Room Temperature, which is officially designated as 20 C to 25 C (68 F to 77 F). The medicine must be kept in a closed, light-resistant container and be explicitly protected from moisture and excessive heat. It is required to keep the product from freezing to maintain stability.

Packaging and Child Safety

To ensure safety, the product is dispensed in a container with a child-resistant closure. The regulatory labeling requires that the medicine must be kept out of the reach of children at all times.

Disposal Requirements

Due to its classification as a Schedule III controlled substance, Anoran should not be kept once it is outdated or no longer needed. Patients are instructed to ask a healthcare professional or pharmacist how to safely dispose of unused medicine, utilizing official drug take-back programs when available. The product must be stored in a safe place to prevent theft.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Anoran found in:

A-Z Index: